In conclusion, HER2 mutations seem to have a significant predictive value for anti-HER2 therapy in NSCLC; for this reason, large biomarker screening programs, such as the French National Program or the US Lung Cancer Mutation Consortium (LCMC), have proposed systematic testing for HER2 mutations in NSCLC [52]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.